Search Bar & Filters
Found 2 Actively Recruiting clinical trials
Actively Recruiting
Researchers are collecting and analyzing medical records from patients with relapsed or refractory multiple myeloma RRMM who have received the treatments teclistamab or talquetamab outside of clinical trials. The study aims to describe how these treatments are used and their effects in real-world settings, focusing on patients who received these therapies during specific time periods. This observational study is sponsored by Janssen-Cilag Ltd. Participants are grouped based on when they first received teclistamab or talquetamab, covering periods up to December 2025 for teclistamab and December 2023 for talquetamab. The study does not involve administering treatments directly but collects retrospective data from medical records to describe treatment use. Data from multiple cohorts are compiled to understand outcomes following these T-cell redirector therapies. Participants medical records are reviewed to gather information on baseline characteristics, response rates, survival, and safety management over up to 40 months. Researchers track overall response rate, time to response, duration of response, minimal residual disease, overall survival, progression-free survival, and time to next treatment. The study also assesses how the treatments are managed in real-world practice, with no direct interventions or visits required from participants during this observational study.
Actively Recruiting
Researchers are creating a national registry in Italy for people with Noonan syndrome, a rare genetic condition that can affect growth, the heart, and other parts of the body. Because this condition is uncommon, doctors have limited information about its progression. This study aims to gather detailed data on signs, symptoms, gene changes, growth patterns, health problems, and the effects of growth hormone treatment over time. Doctors at participating centers will securely enter health information of individuals with genetically confirmed Noonan syndrome into an online platform. This includes personal details, medical history, genetic test results, treatments, and heart check results, with follow-up heart evaluations approximately every two years. The registry will include both existing patients and newly diagnosed individuals, with updates over time. Participants will be monitored through their ongoing medical care, with data collected on their health status and treatments. The study will last five years and aims to establish a comprehensive database to help guide long-term care recommendations and support future clinical trials. Participation is voluntary, and no new treatments are tested in this study.